Bonnie H. Anderson, born in 1963, brings her extensive knowledge in biotechnology to Veracyte, Inc., where she served as the CEO from 2013 until 2021. With a Bachelor’s degree in Biology from UC San Diego and an MBA from Wharton,...

Bonnie H. Anderson, born in 1963, brings her extensive knowledge in biotechnology to Veracyte, Inc., where she served as the CEO from 2013 until 2021. With a Bachelor’s degree in Biology from UC San Diego and an MBA from Wharton, she combines scientific expertise with business acumen. Anderson's leadership at Veracyte was marked by significant growth and innovation in the life sciences sector, making transformative contributions to diagnostics and healthcare. While her official salary was a solid $550,000 in 2017, Anderson is known for a compensation model focused more on performance than on just numbers. Under her watch, Veracyte achieved impressive milestones, including expanding its product pipeline and driving the company’s revenue growth. Importantly, her equity awards reflect a long-term commitment to the company's success, aligning her interests with that of shareholders. Today, Anderson is recognized not just for financials but for steering the company towards breakthroughs in patient diagnostics.

Quick Links

1. Rivals

2. Holdings

3. Insider Trading

4. Compensation History

5. Other Veracyte CEOs

V

Bonnie H. Anderson

Founder and Ex-CEO of Veracyte

Education

B.S. in Biology from the University of California, San Diego and an M.B.A. from the Wharton School of the University of Pennsylvania.

Field of Expertise

Healthcare & Life Sciences - Biotechnology

Sector of Economy

Healthcare

Born

January 1, 1963 - 62 years ago

CEO of Veracyte for

8 years 3 months (Apr 2013 - Jul 2021)

Previous Experience

President and Chief Executive Officer of Veracyte, Inc. since its founding in 2013, previously held various executive roles in the biotechnology and life sciences industries.

Rivals

Competitors/colleagues of Bonnie H. Anderson

B

John Evans

CEO of Beam Therapeutics

2023 Compensation

Stock

$0.00

Salary

$685.00K

Bonus

$431.55K

Other

$17.68K

Total Holdings

$24.88M

1

Kimberly J. Popovits

CEO of 10x Genomics, Inc.

2023 Compensation

Stock

$0.00

Salary

$0.00

Bonus

$0.00

Other

$0.00

Total Holdings

$781.77K

A

Chad Robins

Founder and CEO of Adaptive Biotechnologies

2023 Compensation

Stock

$716.86K

Salary

$663.00K

Bonus

$318.24K

Other

$22.32K

Total Holdings

$21.75M

G

AmirAli Talasaz

Founder and CEO of Guardant Health

2023 Compensation

Stock

$0.00

Salary

$1.00

Bonus

$0.00

Other

$26.41K

Total Holdings

$107.58M

Holdings

See how much did Bonnie H. Anderson make over time.

Bonnie H. Anderson's holdings were a critical part of her wealth and incentives. While specific trading or fluctuation details weren't provided, her role as CEO meant she had a decent stock position linked to her performance. At her peak, Anderson’s...

Bonnie H. Anderson's holdings were a critical part of her wealth and incentives. While specific trading or fluctuation details weren't provided, her role as CEO meant she had a decent stock position linked to her performance. At her peak, Anderson’s total compensation reached around $1.87 million in 2015, showcasing her influence on company performance. Notably, her stock options and performance-based equity awards indicated a clear connection between her financial rewards and the company's success. This alignment ensured that as Veracyte prospered, so did Anderson's personal wealth, creating a win-win scenario. Her approach to equity and stock options reflects a commitment to motivating long-term goals. Over the years, her equity expanded, particularly as her role cemented within the company and its growth story.

Mar 18, 2025

B

shares

BRKR @ $47.14

C

shares

CSTL @ $20.49

V

shares

VCYT @ $31.24

Total Stock Sold

$27.67M

VCYT

$26.94M

959,906 VCYT shares

CSTL

$730.99K

19,000 CSTL shares

What if they kept their stock?

If Bonnie H. Anderson didn't sell their stock, today they would have:
Extra VCYT959,906 shares worth $23.31M and CSTL19,000 shares worth $703.38K.
This is -13.23% and $3.66M less than what they got when they sold the stock.

Charitable Transactions

VCYT

103,112 shares

VCYT

Recent Charitable Transactions

VCYT

45,812 shares

VCYT

Nov 10, 2020

Charity

VCYT

50,000 shares

VCYT

Aug 6, 2020

Charity

VCYT

7,300 shares

VCYT

Mar 11, 2019

Charity

Insider Trading

See recent insider trades of Bonnie H. Anderson.

VCYT

$749.36K

VCYT at $22.04/share

Apr 14, 2023

Sale

VCYT

$773.89K

VCYT at $22.76/share

Mar 15, 2023

Sale

VCYT

$900.06K

VCYT at $26.47/share

Jan 17, 2023

Sale

VCYT

$1.59M

VCYT at $25.13/share

Jan 11, 2023

Sale

VCYT

$2.26M

VCYT at $28.21/share

Dec 1, 2022

Sale

VCYT

$3.36M

VCYT at $27.59/share

Aug 5, 2022

Sale

VCYT

17,667 shares

VCYT

Mar 3, 2022

Received

VCYT

$130.48K

VCYT at $50.18/share

Sep 17, 2021

Sale

VCYT

$95.05K

VCYT at $50.03/share

Sep 10, 2021

Sale

VCYT

20,000 shares

VCYT

Feb 26, 2021

Received

Compensation History

See how much did Bonnie H. Anderson make over time.

In 2021, Bonnie H. Anderson reported zero compensation as a direct salary, a notable shift from previous years where her total compensation included significant bonuses and stock options. In 2015, her highest reported earning was around $1.87 million, driven by a mix of salary, bonus, and vested stock options, reflecting her effective leadership. Each year, her salary and bonuses adapted based on the company’s performance metrics. In 2020, she earned about $1.18 million, including a solid bonus that celebrated the achievement of corporate goals. Her compensation pattern signals a philosophy that prioritizes aligning executive pay with the company’s success rather than emphasizing fixed salaries alone. This strategy not only motivates performance but also encourages retention and objective-focused leadership.

Year

2021

Total Compensation

$0.00

Salary

$0.00

Board Justification

The compensation philosophy aligns with company performance and retention strategies, focusing on competitive market data and executive contributions.

Bonus

$0.00

Board Justification

No bonus was reported for 2021.

Other

$0.00

Board Justification

No other compensation was reported for 2021.

Restricted Stock

$0.00(0 common stock)

Board Justification

No stock was reported as vested in 2021.

Performance Metrics

Performance metrics for compensation determination were not specified in the provided section.

Other Veracyte CEOs

Here are other CEOs of Veracyte

Rebecca Chambers

CEO of Veracyte

July 2021 - Present